Takeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor – has failed to show a benefit in patients with blood cancers, placing i
Three years ago, Johnson & Johnson set up a wide-ranging initiative with Boston University to try to improve lung cancer survival rates through prevention and early intervention.
Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.
Pfizer is the latest big pharma company to take a position on drugs that target CD47 – a 'don't eat me' signal that protects cancer cells from being attacked by the immune system.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
